Related Experiment Video

Updated: Jul 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced

Elena V Shashkova1, Jacqueline F Spencer, William S M Wold

  • 1VirRx Inc., St. Louis, Missouri, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 28, 2006
PubMed

Insights

Novel oncolytic adenoviruses (Ad) engineered with interferon-alpha (IFN-alpha) expression and a specific E1A gene mutation show enhanced antitumor potency and cancer specificity. This approach improves efficacy while reducing toxicity in preclinical cancer models.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Immunotherapy

Background:

  • Oncolytic adenoviruses (Ad) require novel strategies for improved antitumor potency and cancer specificity.
  • Current approaches often face challenges with efficacy and toxicity.

Purpose of the Study:

  • To develop and evaluate a novel oncolytic Ad vector (KD3-IFN) combining interferon-alpha (IFN-alpha) expression with a specific E1A gene mutation (dl1101/1107).
  • To assess the vector's antitumor efficacy, cancer specificity, and toxicity in preclinical cancer models.

Main Methods:

  • Engineered a conditionally replicative Ad vector (KD3-IFN) with the dl1101/1107 E1A mutation, enabling IFN-alpha expression and adenovirus death protein (ADP) overexpression.
  • Evaluated antitumor activity in human hepatocellular carcinoma xenografts (immunodeficient mice) and hamster kidney cancer models (immunocompetent hamsters).
  • Assessed vector replication sensitivity to IFN-alpha in normal versus cancer cells and systemic toxicity in C57BL/6 mice.

Main Results:

  • KD3-IFN demonstrated significantly higher antitumor activity compared to a control vector in both hepatocellular carcinoma and kidney cancer models.
  • The dl1101/1107 mutation conferred sensitivity to IFN-alpha's antiviral effects in normal cells but not cancer cells, enhancing vector selectivity.
  • Systemic administration of KD3-IFN resulted in reduced vector toxicity in mice.

Conclusions:

  • The combination of Ad oncolysis, ADP overexpression, and IFN-alpha immunotherapy provides a potent three-pronged strategy for enhancing anticancer efficacy.
  • Exploiting the dl1101/1107 mutation offers a mechanism for improved selectivity of IFN-alpha-expressing, replication-competent Ads.
  • This engineered oncolytic adenovirus represents a promising candidate for cancer therapy with improved safety and efficacy profiles.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...